Oncotarget

Reviews:

miR-497 expression, function and clinical application in cancer

Gang Yang, Guangbing Xiong, Zhe Cao, Suli Zheng, Lei You, Taiping Zhang and Yupei Zhao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:55900-55911. https://doi.org/10.18632/oncotarget.10152

Metrics: PDF 1571 views  |   HTML 2374 views  |   ?  


Abstract

Gang Yang1,*, Guangbing Xiong1,*, Zhe Cao1,*, Suli Zheng1, Lei You1, Taiping Zhang1 and Yupei Zhao1

1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

* These authors contributed equally to this work

Correspondence to:

Taiping Zhang, email:

Yupei Zhao, email:

Keywords: miR-497; carcinogenesis; biomarker; clinical application

Received: April 01, 2016 Accepted: June 06, 2016 Published: June 17, 2016

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that inhibit gene expression by binding to the 3’ untranslated region (3’-UTR) of their target mRNAs. Recent studies show that miR-497 plays an important role in various cancers. Here, we summarize the existing studies of miR-497 as following: (1) miR-497 expression in cancer; (2) regulation mechanisms of miR-497 expression; (3) function of miR-497 in cancer; (4) direct targets of miR-497; (5) Clinical applications of miR-497. Recent analyses verify that miR-497 mainly suppresses tumors; however, it also acts as an oncogene in several cancers. Increasing evidence indicates that miR-497 can serve as a diagnostic and prognostic biomarker and is a promising therapeutic target for future clinical applications.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10152